Daniel Van Langenberg
Overview
Explore the profile of Daniel Van Langenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nicolaides S, Vasudevan A, Long T, Van Langenberg D
Intest Res
. 2020 Oct;
19(2):158-170.
PMID: 33040518
Smoking significantly increases the risk of developing and worsens Crohn's disease (CD), yet protects against the development and reduces the severity of ulcerative colitis. It is less clear whether smoking...
12.
Pulusu S, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, et al.
World J Gastroenterol
. 2020 Sep;
26(30):4428-4441.
PMID: 32874055
Background: Vedolizumab (VDZ), a humanised monoclonal antibody that selectively inhibits integrins is approved for use in adult moderate to severe ulcerative colitis (UC) patients. Aim: To assess the efficacy and...
13.
Worland T, Chin K, Van Langenberg D, Garg M, Nicoll A
Ann Gastroenterol
. 2020 Mar;
33(2):162-169.
PMID: 32127737
Background: Infliximab therapy may be associated with drug-induced liver injury (DILI), often resembling a drug-induced autoimmune hepatitis. However, the prevalence of DILI in patients receiving infliximab is unclear. Abnormal liver...
14.
Fang W, Haridy J, Keung C, Van Langenberg D, Saunders B, Garg M
Endosc Int Open
. 2019 Sep;
7(9):E1044-E1048.
PMID: 31475220
Endocuff Vision improves adenoma detection rates in patients without inflammatory bowel disease. This study aimed to investigate the safety and feasibility of Endocuff Vision-assisted high-definition white light endoscopy (HDWLE) with...
15.
Nicolaides S, Vasudevan A, Van Langenberg D
Intest Res
. 2019 Aug;
18(1):130-133.
PMID: 31467260
While patients with inflammatory bowel disease are known to be at increased risk of venous thromboembolism, the risk of arterial thrombosis is less well recognized. Here, we describe the case...
16.
Nicolaides S, Vasudevan A, Van Langenberg D
J Crohns Colitis
. 2019 Aug;
14(2):281.
PMID: 31374121
No abstract available.
17.
Vasudevan A, Beswick L, Friedman A, Moltzen A, Haridy J, Raghunath A, et al.
Dig Liver Dis
. 2018 Mar;
50(7):682-688.
PMID: 29525182
Aims: To assess the utility and tolerability of thiopurine-allopurinol co-therapy in inflammatory bowel disease (IBD) patients with intolerance to thiopurine monotherapy. Methods: A retrospective observational study assessed cases of thiopurine...
18.
Seah D, Choy M, Gorelik A, Connell W, Sparrow M, Van Langenberg D, et al.
J Gastroenterol Hepatol
. 2017 Jun;
33(1):226-231.
PMID: 28618062
Background And Aim: Data supporting the optimal maintenance drug therapy and strategy to monitor ongoing response following successful infliximab (IFX) induction, for acute severe ulcerative colitis (ASUC), are limited. We...
19.
Yao C, Barrett J, Philpott H, Chung A, Van Langenberg D, Garg M, et al.
J Gastroenterol Hepatol
. 2015 Jun;
30(12):1731-9.
PMID: 26095068
Background And Aims: Previous observations suggested that an early rise in breath hydrogen after lactulose (ERBHAL) may identify patients with irritable bowel syndrome (IBS) likely to respond to probiotics. Therefore,...